Clinical Trial Update: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study of the investigational drug THE-630 in advanced Gastrointestinal Stromal Tumors was terminated, with results posted on 2024-06-05.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• THE-630

Snippet

Sponsor: Theseus Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-05